Then, we detected the association between MD2 expression and nine immune checkpoints (PD1, PDL1, PDL2, LAG3, CTLA4, TIGIT, IDO1, CD276, CD47), which are promising immunotherapeutic targets for gliomas (48, 49). The gene discussed is IDO1; the disease is glioma.